Skip to main content

Advertisement

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

The original article was published in Breast Cancer Research 2007 9:R50

Correction

After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 5d. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 was mistakenly cropped out of the final image. The original blot for Fig. 4b., “total EGFR” (or lane 2) is shown below to avoid any misunderstanding of the data. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.

Fig. 4b. Uncropped original blot of “total EGFR” suggests that total EGFR levels increase with gefitinib treatment. However, increases in EGFR expression in response to gefitinib, are not seen across the study, which would suggest this increase is simply an anomaly.

Reference

  1. 1.

    Nicholson IR, et al. Heregulin β1 drives gefitinib-resistant growth, and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2007;9(4):R50.

Download references

Author information

Correspondence to Iain R. Hutcheson.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark